Reneo Pharmaceuticals Inc. (NASDAQ: RPHM)
$1.53
+0.0100 ( +0.66% ) 16.4K
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Market Data
Open
$1.53
Previous close
$1.52
Volume
16.4K
Market cap
$50.80M
Day range
$1.51 - $1.53
52 week range
$0.98 - $9.21
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 1 | May 16, 2024 |
4 | Insider transactions | 1 | May 16, 2024 |
8-k | 8K-related | 51 | May 13, 2024 |
8-k | 8K-related | 13 | May 07, 2024 |
10-q | Quarterly Reports | 62 | May 07, 2024 |
10-k/a | Quarterly Reports | 14 | Apr 26, 2024 |
8-k | 8K-related | 13 | Mar 28, 2024 |
10-k | Annual reports | 81 | Mar 28, 2024 |
8-k | 8K-related | 12 | Feb 23, 2024 |
8-k | 8K-related | 12 | Dec 14, 2023 |